27.05
전일 마감가:
$27.30
열려 있는:
$27.04
하루 거래량:
4,574
Relative Volume:
0.80
시가총액:
$2.51B
수익:
$136.33M
순이익/손실:
$-56.34M
주가수익비율:
-36.05
EPS:
-0.7504
순현금흐름:
$-18.87M
1주 성능:
-6.01%
1개월 성능:
-8.11%
6개월 성능:
-29.96%
1년 성능:
+0.00%
Ascentage Pharma Group International Adr Stock (AAPG) Company Profile
AAPG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
AAPG
Ascentage Pharma Group International Adr
|
27.05 | 2.54B | 136.33M | -56.34M | -18.87M | -0.7504 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Ascentage Pharma Group International Adr Stock (AAPG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-13 | 개시 | Rodman & Renshaw | Buy |
| 2025-12-04 | 개시 | Oppenheimer | Outperform |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-10 | 개시 | BTIG Research | Buy |
| 2025-11-05 | 개시 | Piper Sandler | Overweight |
| 2025-03-27 | 개시 | JP Morgan | Overweight |
모두보기
Ascentage Pharma Group International Adr 주식(AAPG)의 최신 뉴스
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update - Defense World
Ascentage Pharma Details 2026 Global Innovation Strategy at J.P. Morgan Healthcare Conference - TipRanks
Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire Inc.
Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap DownWhat's Next? - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap UpWhat's Next? - MarketBeat
Ascentage Pharma Wins FDA IND Clearance for BTK Degrader APG-3288 to Enter Global Phase I Trial - TipRanks
Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288 - Sahm
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives $48.50 Average Price Target from Brokerages - Defense World
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 5.5%Should You Sell? - MarketBeat
Ascentage Pharma to Present at J.P. Morgan Healthcare Conference - TipRanks
Ascentage Pharma to Engage Investors at December 2025 Conferences - MSN
Ascentage Pharma Showcases Promising Data for Olverembatinib at ASH 2025 - The Globe and Mail
Ascentage Pharma showcases promising data for olverembatinib at ASH 2025 - MSN
Ascentage Pharma Unveils Promising Lisaftoclax Data at ASH 2025 - The Globe and Mail
Cash per share of Ascentage Pharma Group International Unsponsored ADR – LSX:A40ZYR - TradingView
ETFs Investing in Ascentage Pharma Group International Unsponsored ADR Stocks - TradingView — Track All Markets
Cash per share of Ascentage Pharma Group International Unsponsored ADR – LS:A40ZYR - TradingView
Ascentage Pharma to Highlight Key Data from ASH 2025 in Upcoming Webcast - TipRanks
Ascentage Pharma Announces New RSU and Share Option Grants - TipRanks
Analysts’ Top Healthcare Picks: Amgen (AMGN), Opus Genetics (IRD) - The Globe and Mail
Ascentage Pharma’s Olverembatinib Shows Promise in Rare GIST Treatment - TipRanks
Ascentage Pharma Group International (NASDAQ:AAPG) Now Covered by Analysts at Truist Financial - Defense World
Ascentage Pharma Group International ADR (AAPG) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Ascentage Pharma Group International ADR (AAPG) Stock Price Today | Live Chart & News - Traders Union
Ascentage Pharma Group International ADR (AAPG) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 12.2%Should You Sell? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), NeurAxis, Inc. (NRXS) and Celcuity (CELC) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: AMN Healthcare Services (AMN) and Crispr Therapeutics AG (CRSP) - The Globe and Mail
Promising Potential of Ascentage Pharma’s Key Assets: Olverembatinib and Lisaftoclax Drive Buy Rating Amidst Risks - TipRanks
Free cash flow per share of Ascentage Pharma Group International Unsponsored ADR – SWB:36X0 - TradingView
Ascentage Pharma to Engage Investors at November Conferences - TipRanks
Centurion Acquisition Corp. (NASDAQ:ALFUW) Short Interest Down 57.1% in October - Defense World
Ascentage Pharma Group International Adr (AAPG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):